Free Trial
→ Collect $7k per month from Tesla’s SECRET dividend (From Investors Alley) (Ad)

Skye Bioscience Q1 2024 Earnings Report

Skye Bioscience logo
$2.98 -0.15 (-4.79%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

Skye Bioscience EPS Results

Actual EPS
-$0.18
Consensus EPS
-$0.16
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Skye Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Skye Bioscience Announcement Details

Quarter
Q1 2024
Date
5/10/2024
Time
N/A

Conference Call Resources

Skye Bioscience Earnings Headlines

We're Hopeful That Skye Bioscience (NASDAQ:SKYE) Will Use Its Cash Wisely
February 22 at 9:04 AM | finance.yahoo.com
Skye Bioscience to Present at TD Cowen Health Care Conference
February 20 at 7:00 AM | globenewswire.com
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
February 22, 2025 | Investors Alley (Ad)
Skye Bioscience's SWOT analysis: nimacimab's potential reshapes obesity stock landscape
February 17, 2025 | msn.com
Leo Miller: Page 3
February 12, 2025 | entrepreneur.com
Craig-Hallum Reaffirms Their Buy Rating on Skye Bioscience (SKYE)
February 6, 2025 | markets.businessinsider.com
See More Skye Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Skye Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Skye Bioscience and other key companies, straight to your email.

About Skye Bioscience

Skye Bioscience (NASDAQ:SKYE), a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

View Skye Bioscience Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles